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Dear Colleagues,
The 53rd European Association for the Study of 
Diabetes Annual Meeting (EASD 2017) was held on 
11–15 September 2017 in Lisbon, Portugal. It was 
attended by around 15,000 physicians from around 
the world who had the opportunity to discuss and 
exchange experiences on key issues of contemporary 
diabetes. Many interesting reports presented during the 
Congress discussed, among others, epidemiology, new 
possibilities associated with molecular biology in the 
practical aspect of translation of basic sciences into da-
ily clinical practice, the problem of obesity and related 
insulin resistance, vascular complications of diabetes 
and new therapies, especially in terms of cardiovascular 
risk. Due to the progressive nature of the disease and 
the gradual deterioration of pancreatic b-cell function, 
glycaemic control still remains difficult, which stimu-
lates the search for new directions and optimal thera-
pies. And it is the results of recent studies assessing new 
therapies, their effects on the optimization of metabolic 
control, the risk of hypoglycaemia and the primary and 
secondary prevention of cardiovascular complications, 
but also the cerebrovascular and renal protection, that 
raised the most interest and hope for the change of 
treatment philosophy. However, after previous pro-
mising data from the LEADER and SUSTAIN-6 studies, 
the results of the Exenatide Study of Cardiovascular 
Event Lowering (EXSCEL) with another GLP-1 agonist, 
exenatide, administered once a week were slightly 
disappointing. The study included 14,752 type 2 dia-
betic patients with median disease duration of about 
12 years, of which 73.1% had a positive CVD history. 
It has been shown that exenatide does not increase 
cardiovascular risk, the risk of hospitalization due to 
heart failure or the risk of inflammation or pancreatic 
cancer. However, no significant reduction was found 
in primary endpoint defined as cardiovascular death, 
myocardial infarction, or non-fatal stroke (11.4% 
vs. 12.2%; HR = 0.91, p = 0.06) and the observed 
reduction in total mortality was not associated with 
a reduction in cardiovascular mortality. Thus, the que-
stion remains whether the GLP1 agonists differ in their 
ability of signal transmission and the biological effects 
exerted. Another interesting direction of research is the 
use of drugs that affect sodium-glucose cotransport, 
in combination with insulin, in type 1 diabetes. In the 
InTandem3 study (Study to Evaluate the Safety of So-
tagliflozin in Patients With Type 1 Diabetes Who Have 
Inadequate Glycaemic Control With Insulin Therapy 
Alone) with sotagliflozin, a SGLT1/SGLT2 inhibitor, 
attention was paid to the potential benefits, but also 
threats, of such therapy associated with increased risk 
of ketoacidosis. Primary endpoint was HbA1c < 7.0% 
after 24 weeks of follow-up without severe episodes of 
hypoglycaemia or diabetic ketoacidosis (DKA). This goal 
was achieved by significantly more patients in the sota-
gliflozin group — 29.6% vs. 15.8%, p < 0.001. Similar 
percentages of documented episodes of hypoglycaemia 
were observed in both groups, but the incidence of 
severe hypoglycaemia was significantly lower in the 
sotagliflozin group than in the control group (11.8% 
vs. 15.4% per patient-year of observation). Unfortuna-
tely, in the sotagliflozin group there were more cases of 
DKA (8.6% vs. 2.4%). The difference was higher among 
patients using personal insulin pumps compared to 
those on multiple injection regimen, suggesting that, 
at least in part, the cause was rather the device failure 
than the study drug itself. More encouraging, at this 
stage of research, were the results of observation in 
type 1 diabetes patients receiving dapagliflozin — the 
DEPICT-1 (Dapagliflozin Evaluation in Patients With 
Inadequately Controlled Type 1 Diabetes) study. In this 
study, the addition of dapagliflozin, regardless of the 
dose applied (5 or 10 mg), to insulin, when failed to be 
sufficiently effective, resulted in a significant reduction 
in HbA1c [5 mg vs. placebo — 0.42% (p < .0001); 10 mg 
vs. placebo — 0.45% (p < .0001)], weight loss [5 mg 
vs. placebo — 2.96% (p < .0001); 10 mg vs. placebo 
— 3.72% (p < .0001)] and a decrease in the daily insulin 
requirement [5 mg vs. placebo — 8.8% (p < .0001); 
10 mg vs. placebo — 13.2% (p < .0001)]. The percen-
tage of hypoglycaemic episodes and adverse events, in-
cluding DKA, was comparable between groups. Despite 
such promising results, the question remains whether 
the observed weight loss would be a desirable outcome 
in type 1 diabetic patients with normal BMI, as well as 
a decrease in systolic BP in patients with low baseline 
values and, finally, if the reduction in insulin dose in 
a group of patients with low initial insulin requirement 
would be as safe as in the study. It is also important 
to precisely identify patients with type 1 diabetes who 
are particularly exposed to ketosis, when using the 
SGLT2 inhibitor in combination with insulin.
The current issue of “Clinical Diabetology”, like 
the previous one, also includes interesting reports 
on diagnostic and therapeutic options that, I hope, 
will support your daily practice. I would like highlight 
again that medicine is still an art that often does not 
know easy ways or fully predictable solutions, and 
that diabetes treatment should always be of benefit 
to the patient.
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